11月13日(路透社)- Arcutis Biotherapeutics Inc.(以下简称“Arcutis Canada”)宣布,健康加拿大已批准ZORYVE泡沫0.3%用于12岁及以上成人和青少年的头皮和身体银屑病。
11月13日(路透社)- Arcutis Biotherapeutics Inc.(以下简称“Arcutis Canada”)宣布,健康加拿大已批准ZORYVE泡沫0.3%用于12岁及以上成人和青少年的头皮和身体银屑病。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.